Aclarion, Inc. (NASDAQ:ACON) Short Interest Up 19.8% in January

Aclarion, Inc. (NASDAQ:ACON) was the target of a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 178,163 shares, an increase of 19.8% from the January 15th total of 148,674 shares. Based on an average daily volume of 159,610 shares, the short-interest ratio is currently 1.1 days. Currently, 21.0% of the shares of the company are short sold. Currently, 21.0% of the shares of the company are short sold. Based on an average daily volume of 159,610 shares, the short-interest ratio is currently 1.1 days.

Analyst Upgrades and Downgrades

ACON has been the subject of a number of research reports. Wall Street Zen cut Aclarion from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Aclarion Price Performance

NASDAQ:ACON opened at $2.58 on Tuesday. The firm has a market capitalization of $2.19 million, a price-to-earnings ratio of -0.17 and a beta of 1.44. Aclarion has a one year low of $2.34 and a one year high of $229.50. The business has a fifty day moving average price of $4.51 and a 200-day moving average price of $6.36.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.